| Stereochemistry | ACHIRAL |
| Molecular Formula | C25H24ClN3O3S |
| Molecular Weight | 481.994 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC(=CC=C1OCCN2CCCC2)N3C=NC4=C(SC(=C4)C5=CC=C(Cl)C=C5)C3=O
InChI
InChIKey=MWULMTACIBZPGN-UHFFFAOYSA-N
InChI=1S/C25H24ClN3O3S/c1-31-22-14-19(8-9-21(22)32-13-12-28-10-2-3-11-28)29-16-27-20-15-23(33-24(20)25(29)30)17-4-6-18(26)7-5-17/h4-9,14-16H,2-3,10-13H2,1H3
| Molecular Formula | C25H24ClN3O3S |
| Molecular Weight | 481.994 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
GW-803430 is centrally active and selective antagonist of melanin-concentrating hormone receptor (MCHR) 1.
GlaxoSmithKline was developing orally active, potent and selective GW-803430 for the treatment of obesity.
GW803430 produces robust antiobesity and antidepressant-like effects in rodents.
CNS Activity
Originator
Approval Year
PubMed
Sample Use Guides
GW803430 attenuated food intake in rats on intermittent access to sucrose at all doses examined (3, 10, 30 mg/kg ip).
Effective doses of GW803430 (1 and 3 mg/kg p.o.) were correlated with antiobesity activity in a 14-day study of diet-induced obese rats.
Route of Administration:
Other
